Abbott Laboratories, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $145.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Josh Jennings has given his Buy rating due to a combination of factors that point to sustained, above-market performance for Abbott Laboratories. He expects the company’s fourth-quarter results to at least meet, and potentially exceed, consensus estimates on both revenue and earnings per share, supported in part by a favorable foreign-exchange tailwind. The company has already signaled comfort with current Street projections for 2026, which embed solid high-single-digit organic sales growth and double-digit EPS expansion. Jennings also views Abbott’s strong recent momentum in its Medical Devices franchise, which has been growing at a robust double-digit organic rate, as a key confirmation of the company’s underlying strength.
In addition, his outlook does not yet factor in the incremental upside from the planned acquisition of Exact Sciences (EXAS), which is expected to close in 2026 and should provide another growth lever over time. Beyond M&A, Jennings highlights that Abbott has multiple internal growth engines in place for the coming year, including the continued rollout and adoption of its Libre diabetes platform and the contribution from its Volt technology. Taken together, these elements support his view that Abbott is well positioned to deliver consistent, reliable growth and outperform expectations, justifying his Buy rating on the stock.
In another report released on January 16, Bank of America Securities also maintained a Buy rating on the stock with a $150.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.